News Category: Company Statement

Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)

— U.S. FDA revises Boxed Warning to clarify that NUPLAZID can be used to treat patients with Parkinson’s disease-related hallucinations and delusions who also have dementia SAN DIEGO — September 18, 2023 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has made two changes to the NUPLAZID […]